|Summary sheet: LSZ|
|Common names||LSZ, LA-SS-Az, Diazedine, Lambda|
|Substitutive name||Lysergic acid 2,4-dimethylazetidide|
|Routes of Administration|
Lysergic acid 2,4-dimethylazetidide (also known as λ, Lambda, and LSZ) is a synthetic psychedelic of the lysergamide chemical class which produces LSD-like psychedelic effects when administered.
In the 2000s, a team led by David E. Nichols at Purdue University set to develop a rigid analog of LSD with the diethylamide group constrained into an azetidine ring in order to map the binding site at the 5-HT2A receptor.
LSZ has little to no history of human usage prior to 2012 when it appeared on some research chemical markets in the UK. LSZ later gained international popularity through a small cluster of mail-order novel psychedelic shops that appeared in 2012. There have also been several unconfirmed reports of LSZ being synthesized in illicit laboratories and distributed on blotter paper or in liquid solution under names such as "Diazedine" and "λ" (or "Lambda").
LSZ is not considered to be addictive or physiologically toxic. Nevertheless, adverse psychological reactions such as severe anxiety, paranoia and psychosis are always possible, particularly among those predisposed to mental illness. It is highly advised to use harm reduction practices if using this substance.
LSZ, or d-lysergic acid 2,4-dimethylazetidide, is a semi-synthethic alkaloid of the lysergamide famiy. It contains a core structure of lysergic acid with an amine functional group bound to RN of the chemical structure. This core polycyclic structure is an indole derivative, and has tryptamine and phenethylamine groups embedded within it.
The structure contains a bicyclic hexahydroindole fused to a bicyclic quinoline group (lysergic acid). At carbon 8 of the quinoline, an amide group is bound. Additionally, the substitutions of the terminal nitrogen atom of the amide group form a 2,4-dimethylazetidide group. LSZ is additionally substituted at carbon 6 with a methyl group.
There are three possible stereoisomers around the azetidine ring with the (S,S)-(+) isomer being the most active. It is slightly more potent than LSD itself in drug discrimination tests using trained rats.
LSZ likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from LSZ's efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
|This subjective effects section is a stub.|
As such, it is still in progress and may contain incomplete or wrong information.
You can help by expanding or correcting it.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
- Drifting (melting, breathing, morphing and flowing)
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- Analysis enhancement
- Conceptual thinking
- Creativity enhancement
- Emotion enhancement
- Immersion enhancement
- Increased music appreciation
- Memory suppression
- Novelty enhancement
- Personal bias suppression
- Spirituality enhancement
- Thought acceleration
- Thought disorganization
- Thought loops
- Time distortion
- Unity and interconnectedness
Anecdotal reports which describe the effects of this compound within our experience index include:
Additional experience reports can be found here:
Toxicity and harm potential
This toxicity and harm potential section is a stub.
As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
The toxicity and long-term health effects of recreational LSZ do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because LSZ is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried LSZ suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
LSZ is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of LSZ is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). LSZ presents cross-tolerance with all psychedelics, meaning that all psychedelics will have a reduced effect after the consumption of LSZ.
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
- Lithium - Lithium is commonly prescribed for the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
- Cannabis - Cannabis may have an unexpectedly strong and unpredictable synergy with the effects of LSZ. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid unintentional overdose.
- Stimulants - Stimulants like amphetamine, cocaine or methylphenidate affect many parts of the brain and alter dopaminergic function. This combination can increase the risk of anxiety, paranoia, panic attacks, and thought loops. This interaction may also result in an elevated risk of mania and psychosis.
- Tramadol - Tramadol is well-documented to lower the seizure threshold and psychedelics may act to trigger seizures in susceptible individuals.
- Denmark: As of August 25, 2015, LSZ is specifically named on the list of illegal substances in Denmark.
- Germany: LSZ is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
- Japan: LSZ is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell.
- Latvia: LSZ is illegal in Latvia. Although it isn't officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
- Sweden: Following its sale as a designer drug, LSZ was made illegal in Sweden on January 26, 2016.
- Switzerland: LSZ is a controlled substance specifically named under Verzeichnis E. It was added to the list of controlled substances on the December 1, 2015.
- Turkey: LSZ is a classed as drug and is illegal to possess, produce, supply, or import.
- United Kingdom: As of January 7, 2015, LSZ is specifically named in the U.K. Misuse of Drugs Act as a Class A drug.
- ↑ 1.0 1.1 Nichols, D. E.; Frescas, S.; Marona-Lewicka, D.; Kurrasch-Orbaugh, D. M. (2002). "Lysergamides of Isomeric 2,4-Dimethylazetidines Map the Binding Orientation of the Diethylamide Moiety in the Potent Hallucinogenic Agent N,N-Diethyllysergamide (LSD)". Journal of Medicinal Chemistry. 45 (19): 4344–4349. doi:10.1021/jm020153s. eISSN 1520-4804. ISSN 0022-2623. OCLC 39480771. PMID 12213075.
- ↑ 2.0 2.1 Advisory Council on the Misuse of Drugs (ACMD) (June 10, 2014). "Update of the generic definition for tryptamines" (PDF). Government Digital Service. p. 12. Retrieved January 1, 2020.
- ↑ Mike Power (January 29, 2014). "The Drug Revolution That No One Can Stop". Matter. Medium. Retrieved January 7, 2020.
- ↑ Cole, Krystle (2005). Lysergic. Indianapolis: Dog Ear Publishing. ISBN 1-59858-007-8.
- ↑ Hamilton Morris (May 1, 2011). "Life Is a Cosmic Giggle on the Breath of the Universe". VICE. Retrieved January 7, 2020.
- ↑ Lüscher, Christian; Ungless, Mark A. (2006). "The Mechanistic Classification of Addictive Drugs". PLOS Medicine. 3 (11). doi:10.1371/journal.pmed.0030437. eISSN 1549-1676. ISSN 1549-1277. PMID 17105338.
- ↑ Nichols, David E. (2016). Barker, Eric L., ed. "Psychedelics". Pharmacological Reviews. 68 (2): 264–355. doi:10.1124/pr.115.011478. eISSN 1521-0081. ISSN 0031-6997.
- ↑ Strassmann, Rick (1984). "Adverse reactions to psychedelic drugs. A review of the literature". Journal of Nervous and Mental Disease. 172 (10): 577–595. doi:10.1097/00005053-198410000-00001. ISSN 0022-3018. OCLC 1754691. PMID 6384428.
- ↑ Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039.
- ↑ "Bekendtgørelse om euforiserende stoffer - ni nye stoffer tilføjet" (in Danish). Danish Medicines Ageny. August 31, 2015. Retrieved January 1, 2020.
- ↑ "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- ↑ "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
- ↑ "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- ↑ "危険ドラッグの成分３物質を新たに指定薬物に指定" (in Japanese). 厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)]. Retrieved December 2, 2022.
- ↑ "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020.
- ↑ "31 nya substanser klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten [Public Health Agency of Sweden]. January 26, 2016. Retrieved January 1, 2020.
- ↑ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
- ↑ https://resmigazete.gov.tr/eskiler/2017/01/20170112-8.pdf